GUFICBIO Gufic Biosciences Q3 FY26 results (Oct–Dec 2025) and concall
Gufic Biosciences reported a largely flat Q3 FY26 revenue with a slight EBITDA margin compression, primarily due to strategic adjustments in debtor management and domestic branded business. However, strong growth in international business and the Botulinum Toxin segment, coupled with the ongoing ramp-up of the Indore plant and successful EU audit, provide positive momentum for future quarters. The company aims for a minimum of 15% growth in FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 11.1%, net profit down 15.8% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 227 | 230 +13% | 231 +11% |
| EBITDA | 39 | 34 | 27 | 32 | 36 −8% | 36 +6% |
| Net profit | 22 | 19 | 8 | 12 | 15 −32% | 16 −16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
